CEBU, Philippines -- Nuevocor, a Singapore-based preclinical-stage biotech startup, has raised an additional $11.6 million in funding from existing investors, according to regulatory filings.
The filings with Singapore's Accounting and Corporate Regulatory Authority only reflect the equity funding received so far in a round, and the overall funding round could be larger or have other components such as debt. DealStreetAsia has reached out to Nuevocor for confirmation.
